vs
南玻集团（CSGS）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是南玻集团的1.9倍（$622.0M vs $323.1M），Royalty Pharma plc净利率更高（34.4% vs 2.2%，领先32.3%），Royalty Pharma plc同比增速更快（4.8% vs 2.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 4.6%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CSGS vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.9倍
$323.1M
营收增速更快
RPRX
高出2.7%
2.0%
净利率更高
RPRX
高出32.3%
2.2%
两年增速更快
RPRX
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $622.0M |
| 净利润 | $7.0M | $214.2M |
| 毛利率 | 50.0% | — |
| 营业利润率 | 9.0% | 62.4% |
| 净利率 | 2.2% | 34.4% |
| 营收同比 | 2.0% | 4.8% |
| 净利润同比 | -79.7% | 2.9% |
| 每股收益（稀释后） | $0.24 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSRPRX
| Q4 25 | $323.1M | $622.0M | ||
| Q3 25 | $303.6M | $609.3M | ||
| Q2 25 | $297.1M | $578.7M | ||
| Q1 25 | $299.5M | $568.2M | ||
| Q4 24 | $316.7M | $593.6M | ||
| Q3 24 | $295.1M | $564.7M | ||
| Q2 24 | $290.3M | $537.3M | ||
| Q1 24 | $295.1M | $568.0M |
净利润CSGSRPRX
| Q4 25 | $7.0M | $214.2M | ||
| Q3 25 | $20.5M | $288.2M | ||
| Q2 25 | $12.3M | $30.2M | ||
| Q1 25 | $16.1M | $238.3M | ||
| Q4 24 | $34.5M | $208.2M | ||
| Q3 24 | $19.1M | $544.0M | ||
| Q2 24 | $13.8M | $102.0M | ||
| Q1 24 | $19.5M | $4.8M |
毛利率CSGSRPRX
| Q4 25 | 50.0% | — | ||
| Q3 25 | 48.1% | — | ||
| Q2 25 | 49.5% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | 51.3% | — | ||
| Q3 24 | 49.4% | — | ||
| Q2 24 | 47.3% | — | ||
| Q1 24 | 46.5% | — |
营业利润率CSGSRPRX
| Q4 25 | 9.0% | 62.4% | ||
| Q3 25 | 10.0% | 70.1% | ||
| Q2 25 | 10.0% | 36.3% | ||
| Q1 25 | 9.8% | 94.0% | ||
| Q4 24 | 13.4% | 60.9% | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 8.8% | 50.2% | ||
| Q1 24 | 10.8% | -13.0% |
净利率CSGSRPRX
| Q4 25 | 2.2% | 34.4% | ||
| Q3 25 | 6.7% | 47.3% | ||
| Q2 25 | 4.1% | 5.2% | ||
| Q1 25 | 5.4% | 41.9% | ||
| Q4 24 | 10.9% | 35.1% | ||
| Q3 24 | 6.5% | 96.3% | ||
| Q2 24 | 4.8% | 19.0% | ||
| Q1 24 | 6.6% | 0.8% |
每股收益（稀释后）CSGSRPRX
| Q4 25 | $0.24 | $0.49 | ||
| Q3 25 | $0.73 | $0.67 | ||
| Q2 25 | $0.44 | $0.07 | ||
| Q1 25 | $0.57 | $0.55 | ||
| Q4 24 | $1.20 | $0.46 | ||
| Q3 24 | $0.67 | $1.21 | ||
| Q2 24 | $0.48 | $0.23 | ||
| Q1 24 | $0.68 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $618.7M |
| 总债务越低越好 | $539.5M | $9.0B |
| 股东权益账面价值 | $283.7M | $9.7B |
| 总资产 | $1.5B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.90× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CSGSRPRX
| Q4 25 | $180.0M | $618.7M | ||
| Q3 25 | $158.4M | $938.9M | ||
| Q2 25 | $145.9M | $631.9M | ||
| Q1 25 | $136.0M | $1.1B | ||
| Q4 24 | $161.8M | $929.0M | ||
| Q3 24 | $118.4M | $950.1M | ||
| Q2 24 | $110.4M | $1.8B | ||
| Q1 24 | $120.8M | $843.0M |
总债务CSGSRPRX
| Q4 25 | $539.5M | $9.0B | ||
| Q3 25 | $538.6M | $8.9B | ||
| Q2 25 | $537.8M | $8.0B | ||
| Q1 25 | $537.6M | $7.6B | ||
| Q4 24 | $538.5M | $7.6B | ||
| Q3 24 | $539.5M | $7.6B | ||
| Q2 24 | $540.5M | $7.6B | ||
| Q1 24 | $541.5M | $6.1B |
股东权益CSGSRPRX
| Q4 25 | $283.7M | $9.7B | ||
| Q3 25 | $289.5M | $9.6B | ||
| Q2 25 | $290.7M | $9.5B | ||
| Q1 25 | $283.1M | $9.8B | ||
| Q4 24 | $282.6M | $10.3B | ||
| Q3 24 | $288.4M | $10.3B | ||
| Q2 24 | $273.3M | $9.8B | ||
| Q1 24 | $269.3M | $9.9B |
总资产CSGSRPRX
| Q4 25 | $1.5B | $19.6B | ||
| Q3 25 | $1.5B | $19.3B | ||
| Q2 25 | $1.4B | $18.3B | ||
| Q1 25 | $1.4B | $17.6B | ||
| Q4 24 | $1.5B | $18.2B | ||
| Q3 24 | $1.4B | $18.0B | ||
| Q2 24 | $1.4B | $17.7B | ||
| Q1 24 | $1.3B | $16.1B |
负债/权益比CSGSRPRX
| Q4 25 | 1.90× | 0.92× | ||
| Q3 25 | 1.86× | 0.93× | ||
| Q2 25 | 1.85× | 0.84× | ||
| Q1 25 | 1.90× | 0.78× | ||
| Q4 24 | 1.91× | 0.74× | ||
| Q3 24 | 1.87× | 0.74× | ||
| Q2 24 | 1.98× | 0.78× | ||
| Q1 24 | 2.01× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | — |
| 自由现金流率自由现金流/营收 | 17.3% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 8.46× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $141.4M | — |
8季度趋势，按日历期对齐
经营现金流CSGSRPRX
| Q4 25 | $59.2M | $827.1M | ||
| Q3 25 | $47.9M | $702.6M | ||
| Q2 25 | $37.3M | $364.0M | ||
| Q1 25 | $11.5M | $596.1M | ||
| Q4 24 | $82.5M | $742.5M | ||
| Q3 24 | $39.5M | $703.6M | ||
| Q2 24 | $43.1M | $658.2M | ||
| Q1 24 | $-29.4M | $664.6M |
自由现金流CSGSRPRX
| Q4 25 | $55.8M | — | ||
| Q3 25 | $43.9M | — | ||
| Q2 25 | $34.6M | — | ||
| Q1 25 | $7.1M | — | ||
| Q4 24 | $76.6M | — | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $38.8M | — | ||
| Q1 24 | $-34.1M | — |
自由现金流率CSGSRPRX
| Q4 25 | 17.3% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 11.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 13.4% | — | ||
| Q1 24 | -11.6% | — |
资本支出强度CSGSRPRX
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.6% | — |
现金转化率CSGSRPRX
| Q4 25 | 8.46× | 3.86× | ||
| Q3 25 | 2.34× | 2.44× | ||
| Q2 25 | 3.04× | 12.06× | ||
| Q1 25 | 0.71× | 2.50× | ||
| Q4 24 | 2.39× | 3.57× | ||
| Q3 24 | 2.07× | 1.29× | ||
| Q2 24 | 3.12× | 6.45× | ||
| Q1 24 | -1.51× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
